The invention relates to the use of an active agent influencing the expression and/or function of SRF, SRF variants and/or members of the SRF signal transduction pathway for the preparation of a therapeutic drug or a pharmaceutical composition for the treatment of disturbances or illnesses that are linked with SRF-related cellular malfunctions. Furthermore, the invention relates to the use of a substance detecting the above signal elements for the diagnosis of disturbances or illnesses linked with SRF-related cellular malfunctions, a diagnostic kit comprising such substances and a cell line which can be used for screening and identifying active agents or substances influencing the above mentioned signal elements.
展开▼